Hidalgo Medina Manuel 4

What Happened
Manuel Hidalgo Medina, a director of Bristol Myers Squibb Co. (BMY), received an award of 3,996.367 deferred share units (reported as a derivative acquisition) on February 1, 2026. The award is valued at $220,000 based on a $55.05 per-share price. This was an award/grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-02-01; Form 4 filed 2026-02-03 (appears timely).
• Security/transaction: 3,996.367 Deferred Share Units (derivative award), Transaction Code A (award/grant).
• Price/value: $55.05 per share equivalent; total reported value $220,000.
• Shares owned after transaction: Not specified in the provided excerpt.
• Footnotes:
  • F1 — Each Deferred Share Unit (DSU) will convert into one common share upon settlement; DSUs become settleable when the director leaves the board or at a future date the director set.
  • F2 — Amounts include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non‑Employee Directors.

Context
Deferred share units are a common form of director compensation that convert into actual shares at settlement and do not represent an immediate open‑market purchase. Such awards are routine and intended for compensation/deferral rather than a direct signal of the insider’s near‑term trading intent.